Yes, no, maybe: FDA panel delivers mixed verdict on AstraZeneca's asthma rescue medication

AstraZeneca has taken a step toward winning approval of its asthma rescue medication PT027 in adults after a FDA advisory committee voted overwhelmingly that its benefits outweigh the risks. But the panel delivered a split decision on adolescent use and voted against approval in children.